nanoComposix is now a Fortis Life Sciences Company. Learn more + Email Newsletter Signup
Please note: This website will be temporarily shut down for renovations from April 21–22. We apologize for any inconvenience caused and look forward to bringing you an even better online experience. Thank you for your patience and understanding!

How to Ensure a Seamless Tech Transfer of Nanomaterials

When developing a therapeutic for clinical use, technology transfer is a crucial step. This path is often made more challenging when the therapeutic is based on a relatively new technology whose regulation is still being defined, such as nanoparticles.

To navigate this terrain effectively, tapping into the expertise of seasoned regulatory, quality, and CMC personnel, along with collaborating with proficient CDMOs, proves instrumental in streamlining this complex aspect of clinical development.

Designed for the biopharma community, this white paper addresses:

Please fill out this form to download white paper: